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Abstract
Background: MicroRNAs are non-coding RNA molecules that posttranscriptionally regulate expression of target
genes and have been implicated in the progress of cancer proliferation, differentiation and apoptosis. The aim of
this study was to determine whether microRNA-21 (miR-21), a specific microRNA implicated in multiple aspects of
carcinogenesis, impacts breast cancer invasion by regulating the tissue inhibitor of metalloproteinase 3 (TIMP3)
gene.
Methods: miR-21 expression was investigated in 32 matched breast cancer and normal breast tissues, and in four
human breast cancer cell lines, by Taqman quantitative real-time PCR. Cell invasive ability was determined by
matrigel invasion assay in vitro, in cells transfected with miR-21 or anti-miR-21 oligonucleotides. In addition, the
regulation of tissue inhibitor of metalloproteinase 3 (TIMP3) by miR-21 was evaluated by western blotting and
luciferase assays.
Results: Of the 32 paired samples analyzed, 25 breast cancer tissues displayed overexpression of miR-21 in
comparison with matched normal breast epithelium. Additionally, incidence of lymph node metastasis closely
correlated with miR-21 expression, suggesting a role for miR-21 in metastasis. Similarly, each of the four breast
cancer cell lines analyzed overexpressed miR-21, to varied levels. Further, cells transfected with miR-21 showed
significantly increased matrigel invasion compared with control cells, whereas transfection with anti-miR-21
significantly decreased cell invasion. Evaluation of TIMP3 protein levels, a peptidase involved in extarcellular matrix
degredation, inversely correlated with miR-21 expression.
Conclusion: As knockdown of miR-21 increased TIMP3 protein expression and luciferase reporter activity, our data
suggests that miR-21 could promote invasion in breast cancer cells via its regulation of TIMP3.
Background
MicroRNAs (miRNAs) are a class of small, noncoding
RNA molecules of about 22 nucleotides in length that
function as posttranscriptional gene regulators [1-3].
MiRNAs encoded in the genome are transcribed by
RNA polymerase II in the nucleus, where they become
cleaved by Drosha and processed by Dicer[4]. Mature
miRNAs repress protein expression by imperfect base
pairing with the 3’untranslated region (UTR) of target
mRNA, leading to reduced translation and/or degrada-
tion of that mRNA molecule [1-3].
miRNAs regulate various biological processes, includ-
ing development, differentiation, cell proliferation and
apoptosis. Accumulating evidence suggests that altera-
tions of some miRNAs expression may play a role in the
development of human cancers [5-7]. While many
miRNA, including let-7, miR-15 and miR-16 are down-
regulated or deleted in cancers [8-10], oncogenic
miRNAs are frequently overexpressed in tumors. Speci-
fically, miR-21 is overexpressed in very diverse types of
malignancy. miR-21 has been proposed to impact cancer
progression by regulating the tumor suppressor gene
Tropomyosin 1 (TM1) [11]. Further, the anti-prolifera-
tive effect of miR-21 inhibition [12] was inhibited by
inactivation of programmed cell death 4 (PDCD4),
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mal apoptotic signaling.
Endogenous inhibitors of matrix metalloproteinases
(MMPs) play a critical role in extracellular matrix
(ECM) homeostasis[13], and deregulated ECM remodel-
ing contributes to cancer metastasis [14]. Recent evi-
dence suggests that miR-21 promotes glioma [15] and
cholangiocarcinoma [16] invasion by targeting MMP
regulators. As tissue inhibitors of metalloproteinases
(TIMPs) contain a consensus miR-21 binding site
(http://targetscan.org/; http://pictar.mdc-berlin.de/;
http://microRNA.org), and reduced expression of
TIMP3 in breast cancer tissue has been associated with
poor disease-free survival[17], we sought to determine
the role of miR-21 in breast cancer invasion, and to
identify whether miR-21-mediated invasion might be
regulated via TIMP3.
Methods
Human tissue samples and cell lines
Human tissue samples were obtained by surgical resec-
tion from 32 patients with breast cancer, at Shandong
Cancer Hospital and Institute from 2005 to 2006. All
samples, including breast cancer and corresponding
adjacent normal tissues, were preserved in liquid nitro-
gen for 30 min following resection. Informed consents
were obtained from all subjects. Human breast cancer
cell lines BCAP-37 (Chinese Type Culture Collection,
Beijing, China), MCF-7 (American Type Culture Collec-
tion (ATCC) number: HTB-22), MDA-MB-231 (ATCC
number HTB-26), and MDA-MB-435 (ATCC number
HTB-129) were cultured in Dulbecco’s modified Eagle’s
medium (DMEM, GIBCO, USA) containing 10% heat-
inactivated fetal bovine serum (FBS, GIBCO), and main-
tained at 37°C in a humidified atmosphere of 5% CO2.
Cells were passaged every 2-3 days to maintain expo-
nential growth.
qRT-PCR analysis of miRNA-21 and TIMP3 mRNA
expression
Total RNA from tissue and cells were isolated using TRI-
zol reagent (Invitrogen) to obtain both miRNA and
mRNA. For analysis of miR-21 expression, the stem-loop
RT primer, real-time PCR primes and TaqMan MGB
probe were designed as previously described [18]. Briefly,
miRNAs were reverse transcribed into cDNAs by Super-
Script II reverse transcriptase. Real-time PCR was per-
formed using a standard TaqMan PCR protocol
according to manufacturer’s protocols (Applied Biosys-
tems), and relative expression was calculated using the
ΔCT method and normalized to the expression of U6
RNA. Relative levels of TIMP3 mRNA were examined by
SYBR green real-time quantitative reverse transcription-
PCR (qRT-PCR) (Applied Biosystems) and normalized to
b-actin mRNA. The primers for TIMP3 were: forward
primer 5’-AGTTACCCAGCCCTATGA-3’,r e v e r s ep r i m e r
5’-GCAAAGGCTTAAACATCT-3’. All qRT-PCRs were
performed in duplicate, and the data are presented as
mean ± standard error of the mean (SEM).
Oligonucleotide transfections
For miR-21 knockdown, cells were transfected with 50
nM of oligonucleotide with Lipofectamine 2000 (Invitro-
gen), according to the manufacturer’sp r o t o c o l .T h e
sequences used were: 5’-UCAACAUCAGUCU-
GAUAAGCUA-3’ (anti-miR-21 oligonucleotide); and 5’-
CAGUACUUUUGUAGUACAA-3’ (control oligonucleo-
tide). For miR-21 overexpression, cells were transfected
with a synthetic RNA duplex sequence corresponding to
mature miR-21. The sequences were: 5’-UAGCUUAU-
CAGACUGAUGUUGA-3’ (miR-21 oligonucleotide);
and 5’-UUCUCCGAACGUGUCACGUTT-3’ (control
oligonucleotide). All oligonucleotides were synthesized
by Genepharma Co. Ltd. The sequences of the control
oligonucleotides were analyzed by BLAST search to
exclude potential hits in the human transcriptome.
Migration assay
BCAP-37, MCF-7, MDA-MB-231, and MDA-MB-435
cells were transfected with anti-miR-21, miR-21, or con-
trol oligonucleotide, cultured for 48 h, and transferred
onto the top of matrigel-coated invasion chambers (24-
well insert, 8 μm pore size; BD Biosciences) in a serum-
free DMEM. DMEM containing 10% fetal calf serum
was added to the lower chamber as a chemoattractant.
After 20 h incubation, non-migrated cells were removed
from the inner part of the insert with a cotton swab.
Fixation and staining of migrated cells were performed
using 0.1% crystal violet. Cells were quantified by fluor-
escence microscopy (100×).
Western blot analysis
Cell lysates were prepared in lysis buffer (0.15 M
NaCl,50 mM Tris-Cl(pH7.5), 2 mM EDTA, 0.5%Triton-
100, 5 mM DTT, 0.2 mM PMSF, 2 μg/ml apoptinin) fol-
lowing 72 h transfection with either anti-miR-21 or con-
trol oligonucleotide. Protein concentrations of total cell
lysates were measured by Bio-Rad Protein Assay, and 50
ug of total cell lysates per lane was separated by 10%
SDS-PAGE. Immunoblotting was performed with rabbit
anti-TIMP3 (1:500; Chemicon), and rabbit anti b-actin
(1:500; Abcam) primary antibodies. Membranes were
subsequently probed with horseradish peroxidase-conju-
gated secondary antibody (1:5000; Zhongshan Biotech,
China), developed by chemiluminescence and exposed
to X-ray film. Densitometry was performed with gel
imaging system (Alphaimager 2200, Pharmacia Biotech
Co. USA).
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The human TIMP3 3’UTR target site was amplified by
PCR using the primers 5’-TCTAGACAAGGAG-
GAACTTGGGTGA-3’ (forward) and 5’-TCTAGAAA-
TACAGAAGTGTCTCAGC-3’ (reverse). The TIMP3
3’UTR was digested by Xba I, and cloned into the pGL3
luciferase vector (Promega, Madison, Wisconsin, USA)
digested with the same restriction enzyme. This
construct, named pGL3-TIMP3, transfected into MDA-
MB-231 and MDA-MB-435 cell lines. At 5 h after
transfection, cells were transfected again with 50 nM of
anti-miR-21 or control oligonucleotide. Cells were lysed
for luciferase activity was measured 24 h thereafter.
pGL3 was cotransfected and used for normalization.
Each transfection was repeated twice in triplicate.
Statistical analysis
Statistical analysis was performed using the SPSS13.0
software. Values are expressed as mean ± SEM. Differ-
ences/correlations between groups were calculated with
Student’s t test, and Pearson’sc o r r e l a t i o nt e s t .P<0 . 0 5
was defined as being significant.
Results
MiR-21 is overexpressed in breast cancer tissue
Matched normal breast epithelium and breast cancer tis-
sue were obtained from 32 patients treated at Shandong
Cancer Hospital and Institute from 2005 to 2006. The
clinicopathologic findings of each patient are shown in
Table 1. Total RNA was isolated from each sample, and
miR-21 content was determined by TaqMan real-time
PCR. Overexpression of miR-21 were observed in 25 of
32 cancer tissues in comparison with the matched nor-
mal tissues (Fig. 1A; P < 0.05), and miR-21 expression
was significantly higher in patients with lymph node
metastasis (Fig. 1B; P < 0.05).
MiR-21 influences cell invasion of breast cancer lines
The expression of miR-21 was determined in BCAP-37,
MCF-7, MDA-MB-231, and MDA-MB-435 breast can-
cer cell lines (Fig. 2A). Each breast cancer line expressed
elevated levels of miR-21. MDA-MB-231 cells, expres-
sing intermediate levels of miR-21 relative to the other
cell lines, were selected to test the impact of modulation
of miR-21 expression on invasion using a cell migration
assay. Taqman real-time PCR revealed that transfection
of miR-21 or anti-miR-21 caused a 2.4-fold increase and
56% decrease of miR-21 expression in MDA-MB-231
cells, respectively, compared to control oligonucleotides
(Fig. 2B). While miR-21 overexpression resulted in a
37% increase in cell invasion compared to negative con-
trols (P < 0.05), miR-21 silencing resulted in a 34%
decrease in invasive cell number (Fig. 2C; P < 0.05).
Similarly, silencing of miR-21 in MDA-MB-435 cells
( 6 2 %d e c r e a s ei nm i R - 2 1e x p r e s s i o n ,F i g .2 D ) ,w h i c h
contained the highest baseline miR-21 expression, signif-
icantly inhibited cell invasion (48% decrease in invasion,
Fig. 2E). Taken together, these data suggest an essential
role for miR-21 in tumor cell invasion in vitro.
TIMP3 protein expression inversely correlates with
miR-21 content in breast cancer cell lines
As miR-21 regulated TIMP3 expression in glioma and
cholangiocarcinoma, we determined baseline TIMP3
protein expression in each of the four breast cancer cell
lines relative to miR-21 content (Fig. 3A). In cell lines
with high relative miR-21 expression (MDA-MB-435
and MDA-MB-231), a low amount of TIMP3 protein
was observed, whereas cell lines with low relative miR-
21expression (BCAP-37 and MCF-7) displayed relatively
high amounts of TIMP3 protein, resulting in a signifi-
cant inverse correlation between miR-21 expression and
TIMP3 protein content (Fig. 3B; Pearson correlation,
r=- 0 . 9 1 3 ,P<0 . 0 5 ) .H o w e v e r ,a sT I M P 3m R N A
expression was very low in each of the four cell lines, a
significant correlation between miR-21 and TIMP3
mRNA was not detected (data not shown).
The TIMP3 3’-UTR is a target for miR-21
To determine whether suppression of miR-21 impacts
TIMP3 transcription, we quantified TIMP3 mRNA in
MDA-MB-231 and MDA-MB-435 cells (each expressing
high levels of endogenous miR-21) following knockdown
of miR-21 expression. Down-regulation of endogenous
miR-21 (Fig. 4A) led to a 1.3 and 1.4 fold increase in
TIMP3 mRNA in MDA-MB-231 and MDA-MB-435
cells, respectively (Fig. 4B). Similar increases in TIMP3
protein expression following miR-21 knockdown were
observed (Fig. 4C, 4D). These data suggest that TIMP3
is regulated by miR-21 in breast cancer cells. In order to
determine whether the 3’untranslated region of TIMP3
mRNA is a direct functional target of miR-21, we cloned
a 250 bp TIMP3 3’-UTR segment, which includes a
potential target site for miR-21 (Fig. 4E), downstream of
the pGL3 luciferase reporter gene to generate the pGL3-
timp3 vector. This vector was co-transfected into
MDA-MB-435 or MDA-MB-231 cell lines together with
Table 1 Clinicopathologic characteristics of surgically
resected breast cancer speimen.
Factors cases
Tumor size (≥ 2/<2 cm) 24/8
Histological grade (I/II~III) 7/25
Lymph node metastasis (negative/positive) 21/11
Clinical stage (I/II/III~IV) 8/17/7
ER/PR (positive/negative) 21/11
Menopausal status (yes/no) 12/20
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trol. A renilla luciferase vector (pRL-TK) was used to
normalize differences in transfection efficiency. Lucifer-
ase activity in MDA-MB-435 cells co-transfected with
pGL3-timp3 vector and anti-miR-21 oligonucleotides
significantly increased by 38% when compared with
negative control (P < 0.05), whereas luciferase activity in
MDA-MB-231 cells increasedb yo n l y2 0 %( F i g .4 F ) .
These data demonstrate that miR-21 regulates TIMP3
expression at the transcriptional level.
Discussion
In the present study, we identify increased expression of
miR-21 in 78% (25/32) of breast cancer samples analyzed,
as compared to patient-matched normal breast epithe-
lium. Further, we identify that the invasive ability of
breast cancer cell lines closely correlates with miR-21
expression, as incidence of lymph node metastases
increases with miR-21 expression. These data are
consistent with reports indicating that miR-21 expression
increased with advanced clinical stage and shortened sur-
vival of the patients [19], and that miR-21 expression is
associated with poor disease-free survival in early stage
patients [20].
Greater than 50% of miRNA are located at genomic
regions implicated in human cancers, emphasizing the
potential importance of miRNA in cancer progression
[21]. Specifically, the miR-21 gene is located on chromo-
some 17q23.2, which is located within the common fra-
g i l es i t eF R A 1 7 B .T h i sr e g i o ni sf r e q u e n t l yf o u n d
amplified in breast, colon, and lung cancer, consistent
with the fact that miR-21 overexpression is widespread
in many types of cancer, including the breast [22].
Despite the link of miR-21 to carcinogenesis, little is
known regarding the specific mechanism how miR-21
may impact cancer progression.
The correlation of miR-21 expression with tumor
metastasis, and supportive evidence that miR-21 regulates
Figure 1 Overexpression of miR-21 in breast cancer tissue specimens. Total RNA was isolated from matched normal breast epithelium and
breast cancer tissue using Trizol. MiR-21expression was analyzed by TaqMan quantitative real-time PCR and normalized to b-actin expression. A,
Quantification of miR-21 expression in matched normal breast epithelium and breast cancer tissue surgically resected from 32 patients. N, normal
tissue; T, tumor tissue. B, The ratio of miR-21expression, presented as relative T/N ratio of. The T/N ratios were analyzed statistically in patients
with lymph node metastasis or without.*, P < 0.05. n, lymph node metastasis.
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Page 4 of 8Figure 2 miR-21 impacts breast cancer cell invasion in vitro. A, Relative miR-21expression was analyzed by Taqman PCR in four breast
cancer cells. B, MDA-231 cells were transfected with miR21, anti-miR-21 or appropriate control oligonucleotides. Total RNA was isolated and
analysed for miR-21 expression as in A. C, Cell invasion was quantified by Matrigel assay following transfection of MDA-231 cells with miR21,
anti-miR-21 or appropriate control oligonucleotides. The data are standardized against control, and presented as relative cell invasion numbers.
D, Relative miR-21 expression in MDA-435 cells transfected with anti-miR-21 or appropriate control oligonucleotides, determined as in A. E,
Relative cell invasion numbers in MDA-435 cells transfected with anti-miR-21 or appropriate control oligonucleotides, as in C. The data are
representative of three experiments. *, P < 0.05.
Figure 3 TIMP3 protein expression correlates with microRNA-21 content in breast cancer cell lines in vitro.A ,W e s t e r nb l o t
analyses of TIMP3 protein, performed as described in Methods. B, Correlation between miR-21expression and TIMP3 protein levels
(Pearson correlation = -0.905; P < 0.05).
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Page 5 of 8Figure 4 miR-21 regulates TIMP3 expression at the mRNA and protein level by targeting the 3’untranslated region of TIMP3 mRNA.
A, miR-21 expression was analyzed by TaqMan PCR in MDA-231 and MDA-435 cells following transfection with anti-miR-21 or control
oligonucleotides, as in Fig. 2B. B, Relative TIMP3 mRNA expression was analyzed in MDA-231 and MDA-435 cells as described in Methods,
following miR-21 silencing as performed in A. C, Western blot analysis of TIMP3 protein expression in MDA-231 and MDA-435 cells following
miR-21 silencing as performed in A. D, Quantification of relative TIMP3 protein expression in MDA-231 and MDA-435 cells following miR-21
silencing, as performed in A. E, Generation of cDNA encoding the 3’UTR region of TIMP3 containing a miR-21 binding site. cDNA was
subsequently cloned into a Luciferase reporter plasmid. F, Determination of the impact of miR-21 silencing on pGL3-TIMP3 luciferase expression
in MDA-231 and MDA-435 cells. Data represents two independent experiments performed in triplicate.*, P < 0.05.
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may impact a cell’s metastatic potential. Several factors
suggest that miR-21 may be impacting matrix metallo-
proteinases inhibitors, such as TIMP3, that play a crucial
role in cancer invasion and metastasis[23] including
recent studies that identified TIMP3 as a functional target
of miR-21 in cell invasion and metastasis in glioma and
cholangiocarcinoma[15,16]. As TIMP3 expression is
down-regulated or lost in several tumor types [24-26],
and adenoviral transfer of TIMP3 into HeLa, HT1080
fibrosarcoma, and melanoma cells reduces their invasive-
ness and stimulates apoptosis[27,28], we tested whether
miR-21 may be impacting TIMP3 expression in primary
breast cancer specimen as well as four breast cancer-
derived cell lines. Our findings report for the first time
that microRNA-21 negatively regulates TIMP3 in breast
cancer, and suggests that TIMP3 may be negatively regu-
lated by miR-21 at the transcriptional level via binding of
the 3’UTR of TIMP3 mRNA. Further, we provide evi-
dence that it is this regulation of TIMP3 expression that
impacts cell invasion in vitro. These compelling data sup-
port miR-21 regulation of TIMP3 expression as a novel
mechanism impacting breast cancer invasion. Our studies
suggest that miR-21 regulation of TIMP3 may represent
a novel target for therapeutic intervention to prevent
breast cancer metastasis, and warrant further
investigation.
Conclusion
Our data identify that miRNA-21 is overexpressed in
breast cancer tissues and breast cancer cell lines, pro-
moting breast cancer invasion in multiple cell lines in
vitro. Our study suggests that the effect of miRNA-21
expression on cell invasion may be due to the regulation
of TIMP3 expression.
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